Current therapeutic developments in atrophic age-related macular degeneration

British Journal of Ophthalmology

Volumn 100, Issue 1, 2016, Pages 122-127

  Hanus, Jakub ^a   Zhao, Fangkun ^a,b   Wang, Shusheng ^a,c  

^a Tulane University   (United States)

^b CHINA MEDICAL UNIVERSITY   (China)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ASCORBIC ACID; AVACINCAPTAD PEGOL; BETA CAROTENE; CHOROIDAL BLOOD FLOW RESTORATION AGENT; ECULIZUMAB; EMIXUSTAT; FENRETINIDE; GLATIRAMER; GSK 933776; LAMPALIZUMAB; LIPOFUSCIN INHIBITOR; MC 1101; MRZ 99030; OT 551; RAPAMYCIN; UNCLASSIFIED DRUG; VISUAL CYCLE INHIBITOR; XANTHOPHYLL; ZEAXANTHIN; ZINC;

AGE RELATED MACULAR DEGENERATION; BLINDNESS; CHRONIC INFLAMMATION; CLINICAL EFFECTIVENESS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; EPITHELIUM CELL; EYE BLOOD FLOW; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; GEOGRAPHIC ATROPHY; IMMUNOTHERAPY; PROCEDURES;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; GEOGRAPHIC ATROPHY; HUMANS; IMMUNOTHERAPY; STEM CELL TRANSPLANTATION;

EID: 84952018810     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2015-306972     Document Type: Review

References (81)

1. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014;2:e106-16.
2. Gordois A, Pezzullo L, Cutler H. The Global economic cost of visual impairment. AMD Alliance International, 2010.
3. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008;358:2606-17.
4. de Jong PT. Age-related macular degeneration. N Engl J Med 2006;355:1474-85.
5. Holz FG, Strauss EC, Schmitz-Valckenberg S, et al. Geographic atrophy: clinical features and potential therapeutic approaches. Ophthalmology 2014;121:1079-91.
6. Patel HR, Eichenbaum D. Geographic atrophy: clinical impact and emerging treatments. Ophthalmic Surg Lasers Imaging Retina 2015;46:8-13.
7. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
8. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
9. Zampros I, Praidou A, Brazitikos P, et al. Antivascular endothelial growth factor agents for neovascular age-related macular degeneration. J Ophthalmol 2012;2012:319728.
10. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013;309:2005-15.
11. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-36.
12. Beatty S, Koh H-H, Phil M, et al. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2000;45:115-34.
13. Khandhadia S, Lotery A. Oxidation and age-related macular degeneration: insights from molecular biology. Expert Rev Mol Med 2010;12:e34.
14. Hanus J, Zhang H, Wang Z, et al. Induction of necrotic cell death by oxidative stress in retinal pigment epithelial cells. Cell Death Dis 2013;4:e965.
15. Hashizume K, Hirasawa M, Imamura Y, et al. Retinal dysfunction and progressive retinal cell death in SOD1-deficient mice. Am J Pathol 2008;172:1325-31.
16. Zhao Z, Chen Y, Wang J, et al. Age-related retinopathy in NRF2-deficient mice. PLoS ONE 2011;6:e19456.
17. Ding X, Patel M, Chan CC. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 2009;28:1-18.
18. Cunnusamy K, Ufret-Vincenty R, Wang S. Next-generation therapeutic solutions for age-related macular degeneration. Pharm Pat Anal 2012;1:193-206.
19. Telander DG. Inflammation and age-related macular degeneration (AMD). Semin Ophthalmol 2011;26:192-7.
20. Ebrahimi KB, Handa JT. Lipids, lipoproteins, and age-related macular degeneration. J Lipids 2011;2011:802059.
21. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-9.
22. Edwards AO, Ritter R III, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005;308:421-4.
23. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005;308:419-21.
24. Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 2006;38:458-62.
25. Yates JR, Sepp T, Matharu BK, et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 2007;357:553-61.
26. Zipfel PF, Lauer N, Skerka C. The role of complement in AMD. Adv Exp Med Biol 2010;703:9-24.
27. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;368:2169-81.
28. Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology 2014;121:693-701.
29. Garcia Filho CA, Yehoshua Z, Gregori G, et al. Change in drusen volume as a novel clinical trial endpoint for the study of complement inhibition in age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina 2014;45:18-31.
30. http://www.ophthotech.com/product-candidates/
31. http://www.roche.com/investors/updates/inv-update-2013-08-27.htm
32. Camardo J. The Rapamune era of immunosuppression 2003: the journey from the laboratory to clinical transplantation. Transplantation proceedings 2003;35(3 Suppl):18s-24s.
33. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93.
34. Hands SL, Proud CG, Wyttenbach A. mTOR's role in ageing: protein synthesis or autophagy? Aging (Albany NY) 2009;1:586-97.
35. Wong WT, Dresner S, Forooghian F, et al. Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial. Invest Ophthalmol Vis Sci 2013;54:2941-50.
36. Aharoni R. Immunomodulation neuroprotection and remyelination-the fundamental therapeutic effects of glatiramer acetate: a critical review. J Autoimmun 2014;54:81-92.
37. Cai X, McGinnis JF. Oxidative stress: the Achilles' heel of neurodegenerative diseases of the retina. Front Biosci (Landmark Ed) 2012;17:1976-95.
38. Hollyfield JG, Bonilha VL, Rayborn ME, et al. Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat Med 2008;14:194-8.
39. Suzuki M, Kamei M, Itabe H, et al. Oxidized phospholipids in the macula increase with age and in eyes with age-related macular degeneration. Mol Vis 2007;13:772-8.
40. Dentchev T, Milam AH, Lee VM, et al. Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol Vis 2003;9:184-90.
41. Lindblad AS, Lloyd PC, Clemons TE, et al. Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. Arch Ophthalmol 2009;127:1168-74.
42. Chew EY, Clemons TE, Agrón E, et al. Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology 2013;120:1604-11.e4.
43. Chew EY, Clemons TE, Sangiovanni JP, et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol 2014;132:142-9.
44. Sangiovanni JP, Agron E, Meleth AD, et al. {omega}-3 Long-chain polyunsaturated fatty acid intake and 12-y incidence of neovascular age-related macular degeneration and central geographic atrophy: AREDS report 30, a prospective cohort study from the Age-Related Eye Disease Study. Am J Clin Nutr 2009;90:1601-7.
45. Tanito M, Li F, Anderson RE. Protection of retinal pigment epithelium by OT-551 and its metabolite TEMPOL-H against light-induced damage in rats. Exp Eye Res 2010;91:111-14.
46. Wong WT, Kam W, Cunningham D, et al. Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial. Ophthalmol Vis Sci 2010;51:6131-9.
47. Parsons CG, Ruitenberg M, Freitag CE, et al. MRZ-99030-A novel modulator of Abeta aggregation: I-Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD). Neuropharmacology 2015;92:158-69.
48. http://www.reviewofophthalmology.com/content/d/retinal-insider/c/44883/
49. Holz FG, Bellman C, Staudt S, et al. Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci 2001;42:1051-6.
50. von Ruckmann A, Fitzke FW, Bird AC. Fundus autofluorescence in age-related macular disease imaged with a laser scanning ophthalmoscope. Invest Ophthalmol Vis Sci 1997;38:478-86.
51. Schutt F, Bergmann M, Holz FG, et al. Proteins modified by malondialdehyde, 4-hydroxynonenal, or advanced glycation end products in lipofuscin of human retinal pigment epithelium. Invest Ophthalmol Vis Sci 2003;44:3663-8.
52. Rozanowska M, Jarvis-Evans J, Korytowski W, et al. Blue light-induced reactivity of retinal age pigment. In vitro generation of oxygen-reactive species. J Biol Chem 1995;270:18825-30.
53. Rozanowska M, Pawlak A, Rozanowski B, et al. Age-related changes in the photoreactivity of retinal lipofuscin granules: role of chloroform-insoluble components. Invest Ophthalmol Vis Sci 2004;45:1052-60.
54. Mathieu JM, Schloendorn J, Rittmann BE, et al. Medical bioremediation of age-related diseases. Microb Cell Fact 2009;8:21.
55. Javitt NB, Javitt JC. The retinal oxysterol pathway: a unifying hypothesis for the cause of age-related macular degeneration. Curr Opin Ophthalmol 2009;20:151-7.
56. Radu RA, Han Y, Bui TV, et al. Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci 2005;46:4393-401.
57. Mata NL, Lichter JB, Vogel R, et al. Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina (Philadelphia, Pa) 2013;33:498-507.
58. Kubota R, Boman NL, David R, et al. Safety and effect on rod function of ACU-4429, a novel small-molecule visual cycle modulator. Retina (Philadelphia, Pa) 2012;32:183-8.
59. Kubota R, Al-Fayoumi S, Mallikaarjun S, et al. Phase 1, dose-ranging study of emixustat hydrochloride (ACU-4429), a novel visual cycle modulator, in healthy volunteers. Retina (Philadelphia, Pa) 2014;34:603-9.
60. http://www.ffb.ca/research/research-news/Alkeus-Stargardt.html
61. http://www.alkeuspharma.com/preclinical.html
62. Booij JC, Baas DC, Beisekeeva J, et al. The dynamic nature of Bruch's membrane. Prog Retin Eye Res 2010;29:1-18.
63. Chiou G. Is dry AMD treatable? A new ophthalmic solution may halt disease progression. Retina Today 2012:69-79.
64. Wei Jiang CG. Effects of hydralazine on ocular blood flow and laser-induced choroidal neovascularization. Int J Ophthalmol 2009;2:324-7.
65. Jiang W, Chiou GCY. Effects of hydralazine on ocular blood flow laser-induced choroidal neovascularization. Int J Ophthalmol 2009;2:324-7.
66. Holz FG, Pauleikhoff D, Spaide RF, et al. Age-related Macular Degeneration. Springer Science & Business Media, 2012.
67. Carr AJ, Vugler AA, Hikita ST, et al. Protective effects of human iPS-derived retinal pigment epithelium cell transplantation in the retinal dystrophic rat. PLoS ONE 2009;4:e8152.
68. Cho MS, Kim SJ, Ku SY, et al. Generation of retinal pigment epithelial cells from human embryonic stem cell-derived spherical neural masses. Stem Cell Res 2012;9:101-9.
69. Buchholz DE, Hikita ST, Rowland TJ, et al. Derivation of functional retinal pigmented epithelium from induced pluripotent stem cells. Stem Cells 2009;27:2427-34.
70. Kokkinaki M, Sahibzada N, Golestaneh N. Human induced pluripotent stem-derived retinal pigment epithelium (RPE) cells exhibit ion transport, membrane potential, polarized vascular endothelial growth factor secretion, and gene expression pattern similar to native RPE. Stem Cells 2011;29:825-35.
71. Zhu D, Deng X, Spee C, et al. Polarized secretion of PEDF from human embryonic stem cell-derived RPE promotes retinal progenitor cell survival. Invest Ophthalmol Vis Sci 2011;52:1573-85.
72. Vugler A, Carr AJ, Lawrence J, et al. Elucidating the phenomenon of HESC-derived RPE: anatomy of cell genesis, expansion and retinal transplantation. Exp Neurol 2008;214:347-61.
73. Carr AJ, Vugler A, Lawrence J, et al. Molecular characterization and functional analysis of phagocytosis by human embryonic stem cell-derived RPE cells using a novel human retinal assay. Mol Vis 2009;15:283-95.
74. Becker S, Jayaram H, Limb GA. Recent advances towards the clinical application of stem cells for retinal regeneration. Cells 2012;1:851-73.
75. Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet 2015;385:509-16.
76. Uchida N, Buck DW, He D, et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 2000;97:14720-5.
77. Cuenca N, Fernandez-Sanchez L, McGill TJ, et al. Phagocytosis of photoreceptor outer segments by transplanted human neural stem cells as a neuroprotective mechanism in retinal degeneration. Invest Ophthalmol Vis Sci 2013;54: 6745-56.
78. McGill TJ, Cottam B, Lu B, et al. Transplantation of human central nervous system stem cells-neuroprotection in retinal degeneration. Eur J Neurosci 2012;35:468-77.
79. Sayegh RG, Zotter S, Roberts PK, et al. Polarization-sensitive optical coherence tomography and conventional retinal imaging strategies in assessing foveal integrity in geographic atrophy. Invest Ophthalmol Vis Sci 2015;56:5246-55.
80. Sayegh RG, Kiss CG, Simader C, et al. A systematic correlation of morphology and function using spectral domain optical coherence tomography and microperimetry in patients with geographic atrophy. Brit J Ophthalmol 2014;98: 1050-5.
81. Simader C, Sayegh RG, Montuoro A, et al. A longitudinal comparison of spectral-domain optical coherence tomography and fundus autofluorescence in geographic atrophy. Am J Ophthalmol 2014;158:557-66.